3rd April 2018 Pfizer and Allogene Therapeutics Enter Into Asset Contribution Agreement for Pfizer’s Allogeneic CAR T Immuno-oncology Portfolio
13th December 2017 Pionyr Immunotherapeutics Completes $62 Million Series B Financing to Advance Antibody-based Therapeutics Targeting the Tumor Microenvironment